Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

DMC recommends continuation of phase III Oncophage trial

Jan. 5, 2004

Sixteenth Medarex fully human antibody enters clinical development

Dec. 30, 2003

Genmab files to conduct phase I/II HuMax-CD20 trial for NHL

Dec. 29, 2003

Phase II Pentrix trial cleared to commence

Dec. 23, 2003

Antitumor activity of thalidomide analogues in hematological malignancies

Dec. 22, 2003

Preclinical findings for SGN-40 summarized at ASH meeting

Dec. 19, 2003

Active Biotech TTS development to focus on TTS CD3

Dec. 19, 2003

Potential use of bispecific antibody Bi20 in patients with B-cell lymphoma

Dec. 19, 2003

CC-5013 safe and effective in hematological malignancies

Dec. 18, 2003

Phase I study evaluates Aastrom dendritic cell-based vaccine for GI cancers

Dec. 18, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...